Advances in Nephrology

Clinical Study

Incremental Hemodialysis Schedule in Patients with Higher Residual Renal Function at the Start of Dialysis

Table 3

Clinical and analytical data in twice-weekly and three-weekly hemodialysis schedule along the follow-up period.
  Basal6 months12 months18 months24 months30 months
Group 2 HD/weekOn hemodialysis706141322014
On 2 HD/week7049 (80%)23 (56%)12 (38%)7 (35%)2 (14%)
Anuric patients05 (8%)11 (27%)12 (38%)13 (65%)11 (79%)
RRF (mL/min/1,73 m2)6,35 ± 2,354,31 ± 2,953,39 ± 2,982,75 ± 1,961,71 ± 1,571,18 ± 2,56
Kt/V dialysis—1,42 ± 0,281,48 ± 0,271,45 ± 0,271,50 ± 0,341,58 ± 0,27
Kt/V total—2,13 ± 0,541,96 ± 0,441,88 ± 0,491,81 ± 0,391,75 ± 0,36
nPCR (g/kg/day)—1,02 ± 0,180,97 ± 0,241,01 ± 0,271,08 ± 0,231,07 ± 0,24
eKru (mL/min)—6,39 ± 1,306,12 ± 1,886,45 ± 1,766,65 ± 1,336,67 ± 1,20
Hemoglobin level (g/dL)10,6 ± 1,311,5 ± 1,311,4 ± 111,5 ± 1,311,4 ± 1,111,5 ± 0,9
Erythropoietin dose (IU/week/kg)124 ± 76119 ± 10299 ± 74113 ± 99109 ± 116116 ± 114
B2M level (mg/L)19,3 ± 7,423,7 ± 9,826,2 ± 11,129,7 ± 14,732,9 ± 15,133,9 ± 8,7
Group 3 HD/weekOn hemodialysis645142332318
Anuric patients016 (31%)**25 (60%)**23 (70%)*18 (78%)14 (78%)
RRF (mL/min/1,73 m2)5,22 ± 2,74*2,13 ± 1,66***1,29 ± 1,28***0,85 ± 0,76***0,84 ± 1,20*0,82 ± 1,89
Kt/V dialysis—1,44 ± 0,321,50 ± 0,211,53 ± 0,241,44 ± 0,211,53 ± 0,16
Kt/V total—1,57 ± 0,34***1,58 ± 0,23***1,59 ± 0,25**1,51 ± 0,23**1,61 ± 0,23
nPCR (g/kg/day)—1,06 ± 0,261,03 ± 0,230,96 ± 0,151,07 ± 0,230,92 ± 0,15
eKru (mL/min)—6,54 ± 1,246,42 ± 1,656,80 ± 1,456,65 ± 0,936,62 ± 1,60
Hemoglobin level (g/dL)9,9 ± 1,4**11,3 ± 1,311,4 ± 1,411,1 ± 1,411,3 ± 1,511,5 ± 1,3
Erythropoietin dose (IU/week/kg)143 ± 76163 ± 100*158 ± 111**178 ± 107*151 ± 105145 ± 83
B2M level (mg/L)26,2 ± 9,2***32,2 ± 11***35 ± 9,9***37,7 ± 14,1*39,7 ± 15,238,8 ± 13,2
< 0,05; ** < 0,01; *** < 0,001 (between 2 HD/week and 3 HD/week groups).